GH Research Announces Proposed Public Offering

Company Overview - GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for depression, specifically targeting treatment-resistant depression (TRD) with its proprietary mebufotenin therapies [7]. Offering Details - GH Research PLC has announced a public offering of $150 million of ordinary shares in the United States, with an option for underwriters to purchase an additional $22.5 million of shares [1]. - The offering is subject to market conditions and other factors, with no assurance on the completion or terms of the offering [1]. Underwriters - The joint book-running managers for the offering are Cantor, Stifel, and RBC Capital Markets, with Canaccord Genuity and Citizens JMP acting as co-lead managers [2]. Regulatory Information - A registration statement for the securities was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on March 17, 2023 [3]. - The offering will be conducted through a prospectus supplement and an accompanying prospectus, which will be available free of charge on the SEC's website [3]. Investor Communication - The announcement specifies that it does not constitute an offer to sell or solicit an offer to buy securities in jurisdictions where such actions would be unlawful [4]. - In the EEA and the UK, the offering is directed only at qualified investors with professional experience in investment matters [5][6].